ABL Bio subsidiary Neok Bio officially launches in the US, accelerating development of dual antibody ADCs

CAR-T Digest - August 2020

05 November 2025: ABL Bio subsidiary Neok Bio officially launches in the US, accelerating development of dual antibody ADCs

ABL Bio officially launched its U.S.-based subsidiary Neok Bio, focused on the clinical development of bispecific antibody ADCs, and publicly disclosed for the first time the targets of its two lead assets – ABL206 (NEOK001) and ABL209 (NEOK002)
ABL206 targets ROR1 and B7-H3, while ABL209 targets EGFR and MUC1, both designed to enhance tumor selectivity, penetration, and safety compared to conventional single-antibody ADCs
Preclinical data demonstrated superior efficacy and a wider therapeutic window, highlighting their potential for use across multiple solid tumors
ABL Bio will complete nonclinical studies and IND submissions by late 2025 or early 2026, with Phase 1 trials expected to begin in mid-2026 under Neok Bio’s management, and initial clinical data anticipated in 2027
The launch marks a key step in ABL Bio’s expansion into the U.S. and its growing next-generation ADC portfolio, reinforcing its dual-antibody platform strategy alongside other assets like ABL001, ABL111, and ABL503